| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/23/2003 | WO2001083782A3 Novel proteases |
| 01/23/2003 | WO2001005805A9 Novel c-19-halogen-substituted, 5-substituted, 5-substituted or 6,10 carbocyclically condensed steroids of the androst-9(11)-ene-series, methods for the production and use thereof |
| 01/23/2003 | US20030018222 Sovent extracting the dried marigold flower petals, eluting through an anion exchange resin column, diluting the eluent, crystallization; protecting lutein against deterioration, store for long time |
| 01/23/2003 | US20030018197 Administering a therapeutically effective amount of a pyrrazole sulfide or ether compound to treat the human immunodeficiency virus infection |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018193 Beta-alanine derivatives and their use as receptor anatgonists |
| 01/23/2003 | US20030018189 Cyclic polyamines having total 9-24 members which have activity in against HIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors |
| 01/23/2003 | US20030018186 Monocyclic L-nucleosides, analogs and uses thereof |
| 01/23/2003 | US20030018181 Antiinflammatory agents; culturing; isolation of fusion protein |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018165 Uses of suppressive macrophage activation factors |
| 01/23/2003 | US20030018070 Bisaryl compound and medicament for cancer treatment comprising the same |
| 01/23/2003 | US20030018068 Vanadium (IV) metallocene complexes having spermicidal activity |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018066 Administering vitamin e and selenium, or compound thereof |
| 01/23/2003 | US20030018064 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 01/23/2003 | US20030018060 Therapeutic methods and compositions involving isoflavones |
| 01/23/2003 | US20030018058 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/23/2003 | US20030018049 Azithromycin combination for emesis control in mammals |
| 01/23/2003 | US20030018029 Tyrosine kinase inhbitor; antiproliferative agents |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030018005 Autoimmune disease; antiinflammatory agents; antiallergens; rheumatic diseases; antitumor agents |
| 01/23/2003 | US20030018004 Vector |
| 01/23/2003 | US20030017977 Methods of treating inflammatory skin diseases |
| 01/23/2003 | US20030017974 Side effect reduction of cancer therapy |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017617 Mammalian receptor proteins; related reagents and methods |
| 01/23/2003 | US20030017586 Nucleotide sequences coding polypeptide for use in the treatment of viral diseases |
| 01/23/2003 | US20030017562 Nucleotide sequences coding polypetide for use in the treatment, prevention and diagnosis of gastrointestinal and apoptosis disorders |
| 01/23/2003 | US20030017547 Nucleotide sequences coding polypeptide for use in the treatment of cancer |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017512 Angiostatin receptor |
| 01/23/2003 | US20030017491 Chromogenic in situ hybridization methods, kits, and compositions |
| 01/23/2003 | US20030017468 Nucleotide sequences which code lung preferential gene for use in the treatment and diagnosis of lung cancer |
| 01/23/2003 | US20030017249 Composition for drinking/eating and beverage/food |
| 01/23/2003 | US20030017218 Soft tissue anticancer agents |
| 01/23/2003 | US20030017215 Soft tissue anticancer agents |
| 01/23/2003 | US20030017210 Controlled-release for oral administration of cisplatin |
| 01/23/2003 | US20030017197 Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells |
| 01/23/2003 | US20030017196 Oligonucleotide inhibitors of bcl-xL |
| 01/23/2003 | US20030017164 Dye-azide compounds for dual phototherapy |
| 01/23/2003 | US20030017161 Polypeptides that are capable of modulating apoptosis; also Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 |
| 01/23/2003 | US20030017160 Human checkpoint kinase, hCDS1, compositions and methods |
| 01/23/2003 | US20030017157 Endothelial cell expression patterns |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | US20030017134 Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| 01/23/2003 | CA2707767A1 Biologically active peptides |
| 01/23/2003 | CA2454135A1 Gpcs as modifiers of the irrtk and p21 pathways and methods of use |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453474A1 Vegfr-1 antibodies to treat breast cancer |
| 01/23/2003 | CA2453435A1 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453357A1 Anti-neoplastic viral agents |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2453175A1 Interaction inhibitors of tcf-4 with beta-catenin |
| 01/23/2003 | CA2453169A1 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity |
| 01/23/2003 | CA2453161A1 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | CA2453147A1 Methods of treating cytokine mediated diseases |
| 01/23/2003 | CA2453111A1 Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| 01/23/2003 | CA2452630A1 Use of oxidised lipoproteins for differentiation of precursor cells into mature dendritic cells |
| 01/23/2003 | CA2452517A1 Recombinant vsv for the treatment of tumor cells |
| 01/23/2003 | CA2452491A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | CA2452417A1 Compositions comprising the biologicially active peptide ysl |
| 01/23/2003 | CA2452382A1 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 01/23/2003 | CA2450898A1 Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| 01/23/2003 | CA2447585A1 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | CA2434303A1 Method for obtaining a tgf-beta enriched protein fraction in activated form, protein fraction and therapeutic applications |
| 01/23/2003 | CA2418173A1 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/22/2003 | EP1277843A2 Novel human genes and gene expression products related to colon cancer |
| 01/22/2003 | EP1277836A1 Modulation of the IAPs and NAIP for the treatment of proliferative diseases |
| 01/22/2003 | EP1277754A1 Imidazopyridine derivatives |
| 01/22/2003 | EP1277744A1 Oxadiazole derivatives having anticancer effects |
| 01/22/2003 | EP1277738A1 Condensed heteroaryl derivatives |
| 01/22/2003 | EP1277730A1 Neovascularization inhibitors |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1277472A1 Remedies for cancer |
| 01/22/2003 | EP1277470A1 Injectable galenical formulation for use in photodynamic diagnostic or therapy and process of manufacturing it |
| 01/22/2003 | EP1276902A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 01/22/2003 | EP1276896A2 Method of identifying and producing antigen peptides and use thereof as vaccines |
| 01/22/2003 | EP1276880A2 Polymorphisms in the human cyp2d6 gene promoter region and their use in diagnostic and therapeutic applications |
| 01/22/2003 | EP1276877A2 Agent for postoperative use after the removal of bone tumours |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276863A1 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276853A1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276770A1 Proteins with a high immunoreactivity and a method for the production thereof |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276761A2 New bromodomain protein |
| 01/22/2003 | EP1276760A2 Polyamide nucleic acid derivatives, agents and methods for producing them |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276750A1 Antisense modulation of zinc finger protein-217 expression |
| 01/22/2003 | EP1276740A2 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
| 01/22/2003 | EP1276739A2 Heterocycles that are inhibitors of impdh enzyme |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276736A2 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
| 01/22/2003 | EP1276734A1 Halogenated rhodamine derivatives and applications thereof |